Physician profile
Robert E Mcmichael
NPI 1225070931
$387.02
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $124 · 2022: $20.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $72.16 | 2019-2020 | |
| Pfizer INC. | $57.75 | 2019-2020 | |
| Tersera Therapeutics LLC | $48.20 | 2019 | |
| Biogen, INC. | $39.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.29 | 2019 | |
| Novo Nordisk INC | $23.35 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20.39 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.43 | 2019 | |
| Allergan, INC. | $15.57 | 2020 | |
| Abbott Laboratories | $14.61 | 2020 | |
| Gilead Sciences, INC. | $14.21 | 2020 | |
| Horizon Therapeutics Plc | $12.96 | 2020 | |
| Merck Sharp & Dohme LLC | $11.33 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcmichael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.